ceocoder

Best of luck and please let me know if you want someone to dogfood things as an outsider. My email is my HN username

[0] https://medium.com/galleys/a-postscript-to-into-thin-air-e23...

disclosure: I work at Google as well.

I have been trying to figure out homemade Neapolitan pizza for quite sometime, early on I blamed my oven, then pizza stone, then loud motorcycle down the street. After watching numerous YouTube videos and reading blogs I've settled on this method, it works but requires precision - i.e. one has to use a weightscale and a thermometer, and a pizza steel - pizza stone just didn't work in a regular home oven. Cooking has been a relaxing escape during this pandemic, Neapolitan style pizza requires multiple days of prep and at the end results are delicious delicous pizzas that delivery just can't replicate.

Thank you!

(disclaimer: links to Amazon are affiliate links, I'll see if those can cover the cost of domain, if not I'll just use a generic github or netlify domain)

-Omar Little

(I like this version better)

(d) incorporate any Cloud Products into a product or service you provide to a third party;

does this mean that I can't integrate JIRA into a ticket tracking workflow that I build for my product with IFTTT that creates a new ticket when someone sends an email to a support alias?

(e) interfere with or otherwise circumvent mechanisms in the Cloud Products intended to limit your use;

(f) reverse engineer, disassemble, decompile, translate or otherwise seek to obtain or derive the source code, underlying ideas, algorithms, file formats or non-public APIs to any Cloud Products, except to the extent expressly permitted by applicable law (and then only upon advance notice to us);

(g) remove or obscure any proprietary or other notices contained in any Cloud Product;

Fair enough.

(h) use the Cloud Products for competitive analysis or to build competitive products;

Sure, I mean this is hard to enforce but if the team at Trello was using JIRA while making Trello, Atlassian could just say "hey - stop, no like".

(i) publicly disseminate information regarding the performance of the Cloud Products;

Seriously? I really didn't believe when I saw parent say you are not allowed to comment on performance of the product but I stand corrected. I will not comment on performance of any Atlassian product ever, ever ever. You got me Atlassian, this is what I get for not reading ToS before clicking Accept.

(j) encourage or assist any third party to do any of the foregoing.

Ok.

[0] https://www.atlassian.com/legal/cloud-terms-of-service

I really don't want to store my passwords on your "servers", and I'm sure there are few others like me - not a majority. In our case BitWarden's idea of paying for a subcription (happy to do it), and hosting BitWarden in my own network - pretty close to local vaults in terms of analogy.

I still like the UX of 1Password, if you ever allow local vaults and still charge subscription, I'll sign up on day 1 - I just don't want anything to do with my entire vault being hosted elsewhere, potentially irrational but when it comes to things we store in 1Password and the like - CC #, Passport number, decryption keys, licence codes, launch codes (jk) - I feel OK with my irrational paranoia.

Thanks again for making 1Password!

This was the precise reason I switched to BitWarden 6 months ago, needed a solution where my passwords didn't leave my network.

[0] https://news.ycombinator.com/item?id=10111454

[1] https://news.ycombinator.com/item?id=10114707

They have taken an interesting approach with thumb cluster, single key on farend and 3 on near end of thumb. I did the opposite of that, on account of thumb being not that flexible in bent position.

Over the years my daily driver has been kinesis advantage2. I tried ergodox but really disliked thumbcluster placement and additional middle keys. I made a keeb.io Nyqist recently and got a few pcbs printed for Redox, need to build that out.

It is really hard to go back to non-split keyboards after using split for a while, and kinesis advantage is still the gold standard imo, concave keywell alone is the reason to spend north of $350 on it.

[0] https://github.com/tebeka/nrsc

tl;dr I grew up in India where the Indian Rupee was quite weak compared to the USD. Most people I knew couldn't really afford a legitimate copy of Windows XP - 1 USD was about 48.61 INR in 2002, and average wage was about 120 INR/day[0]. At that price a copy of Windows XP (priced at around $300/$400 ~ INR 14,000) was prohibitively expensive for pretty much everyone I knew. Because of that we ended up using leaked keys to setup new PCs, I did that enough times for my family, friends, and classmates that now I can type that key up as if I'm typing "hello world" :)

[0] https://www.ilo.org/wcmsp5/groups/public/---asia/---ro-bangk...

Great job!

It is easy to dismiss something as "just a chat product" but then again, it is incredibly hard to make a product that is so easy to use that everyone can use. Reminds me of that comment about Dropbox from years ago https://news.ycombinator.com/item?id=9224

”Is it safe?

Yes, but there are side-effects. There were no dangerous side-effects from taking the vaccine, however, 70% of people on the trial developed either fever or headache. The researchers say this could be managed with paracetamol.”

This sounds like really good news, anyone with medical background disseminate this further?

Edit: here is the lancet article posted on /r/COVID19 sub and extract

https://www.thelancet.com/lancet/article/s0140-6736(20)31604...

Background:

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.

Methods

We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18–55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5×10¹⁰ viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.

Findings

Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493–1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96–317; n=127), and were boosted following a second dose (639 EU, 360–792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R²=0·67 by Marburg VN; p<0·001).

Interpretation

ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support largescale evaluation of this candidate vaccine in an ongoing phase 3 programme.

To quote my favorite mathematician specializing in chaos theory, ”Your scientists were so preoccupied with whether or not they could, they didn’t stop to think if they should.“

Did he (or you) end up writing about his experiences post CIA? I’d love to read those.